Open Payments

NICHOLAS J GOETSCH

Type
Physician · Allopathic & Osteopathic Physicians / Family Medicine
Where
WATERLOO, IA
NPI
1740287614
Received
$574,403 in 396 records, 2019 to 2025 ($524,784 general, $49,618 research)
As principal investigator
$3,590,110 of research payments to others in 142 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment28$68,330
2024General payment30$66,695
2024Research payment1$1,900
2023General payment27$47,869
2023Research payment2$1,900
2022General payment57$72,403
2022Research payment4$37,704
2021General payment47$72,763
2021Research payment2$8,114
2020General payment120$114,588
2019General payment78$82,133

By company

CompanyRecordsAmountYears
Takeda Pharmaceuticals U.S.A., Inc.180$406,8572020–2025
Shire North American Group Inc25$58,9462019
Eli Lilly and Company8$47,7182021–2023
Allergan, Inc.86$27,4432019–2020
ABBVIE INC.58$16,5942021–2025
Janssen Pharmaceuticals, Inc32$15,8852019–2022
Kowa Pharmaceuticals America, Inc.5$9202022
CSL Behring1$212019
Genentech USA, Inc.1$152020

By nature of payment

NatureRecordsAmount
Consulting Fee178$464,009
Compensation for services other than consulting, including serving as faculty or as a speaker at a v31$52,040
Research payment9$49,618
Travel and Lodging42$5,824
Food and Beverage136$2,911

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-05Takeda Pharmaceuticals U.S.A., Inc.$2,807Consulting FeeCash or cash equivalent2025
2025-12-05Takeda Pharmaceuticals U.S.A., Inc.$2,807Consulting FeeCash or cash equivalent2025
2025-11-12Takeda Pharmaceuticals U.S.A., Inc.$2,807Consulting FeeCash or cash equivalent2025
2025-11-12Takeda Pharmaceuticals U.S.A., Inc.$2,807Consulting FeeCash or cash equivalent2025
2025-10-16ABBVIE INC.$18Food and BeverageIn-kind items and servicesTEFLARO Drug, ANTI-INFECTIVE2025
2025-10-08Takeda Pharmaceuticals U.S.A., Inc.$2,807Consulting FeeCash or cash equivalent2025
2025-10-08Takeda Pharmaceuticals U.S.A., Inc.$2,807Consulting FeeCash or cash equivalent2025
2025-09-10Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-09-10Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-08-11ABBVIE INC.$18Food and BeverageIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2025
2025-08-08Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-08-08Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-07-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-07-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-06-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-06-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-05-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-05-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-04-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-04-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-03-12Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-03-12Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-02-12Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-02-12Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-02-08ABBVIE INC.$18Food and BeverageIn-kind items and servicesTEFLARO Drug, ANTI-INFECTIVE2025
2025-01-17Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-01-17Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2025-01-15Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2025
2024-12-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-12-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-11-13Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-11-13Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-10-25Takeda Pharmaceuticals U.S.A., Inc.$312Consulting FeeCash or cash equivalent2024
2024-10-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-10-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-10-01ABBVIE INC.$1,900Research paymentCash or cash equivalentA Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Seve2024
2024-09-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-09-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-08-22ABBVIE INC.$17Food and BeverageIn-kind items and servicesTEFLARO Drug, ANTI-INFECTIVE2024
2024-08-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-08-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-07-15Takeda Pharmaceuticals U.S.A., Inc.$1,353Consulting FeeCash or cash equivalent2024
2024-07-12Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-07-12Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-06-10Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-06-10Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-05-10Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-05-10Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-05-06ABBVIE INC.$17Food and BeverageIn-kind items and servicesTEFLARO Drug, ANTI-INFECTIVE2024
2024-04-17Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-04-17Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-03-28ABBVIE INC.$11Food and BeverageIn-kind items and servicesTEFLARO Drug, ANTI-INFECTIVE2024
2024-03-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-03-11Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-02-14Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-02-14Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-01-17Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-01-17Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2024
2024-01-05ABBVIE INC.$14Food and BeverageIn-kind items and servicesTEFLARO Drug, ANTI-INFECTIVE2024
2023-12-15Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2023
2023-12-15Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2023
2023-11-10Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2023
2023-11-10Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2023
2023-11-07ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2023
2023-10-25ABBVIE INC.$25Travel and LodgingIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2023
2023-10-25ABBVIE INC.$13Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2023
2023-10-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2023
2023-10-09Takeda Pharmaceuticals U.S.A., Inc.$2,707Consulting FeeCash or cash equivalent2023
2023-09-20Takeda Pharmaceuticals U.S.A., Inc.$1,955Consulting FeeCash or cash equivalent2023
2023-09-13Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-09-13Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-08-16ABBVIE INC.$12Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2023
2023-07-20ABBVIE INC.$13Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2023
2023-07-14Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-07-14Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-06-14Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-06-14Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-05-09ABBVIE INC.$6Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2023
2023-04-18ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2023
2023-04-07Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-04-07Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-03-29ABBVIE INC.$52Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2023
2023-03-06ABBVIE INC.$11Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2023
2023-02-08Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-02-08Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2023
2023-02-08ABBVIE INC.$17Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2023
2023-01-31Eli Lilly and Company$575Research paymentIn-kind items and servicesA STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2)2023
2023-01-10Eli Lilly and Company$1,325Research paymentIn-kind items and servicesA DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3)2023
2022-12-15Kowa Pharmaceuticals America, Inc.$900Consulting FeeCash or cash equivalentSeglentis Drug, Pain Management2022
2022-12-07Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-12-07Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-12-07ABBVIE INC.$9Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-11-21Eli Lilly and Company$28,114Research paymentCash or cash equivalentASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2022
2022-11-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-11-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-11-04ABBVIE INC.$11Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-10-05Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-10-05Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-09-20ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2022
2022-09-20ABBVIE INC.$28Food and BeverageCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2022
2022-09-20ABBVIE INC.$16Travel and LodgingIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-09-15Janssen Pharmaceuticals, Inc$25Food and BeverageIn-kind items and servicesXARELTO Drug, Cardiovascular & Metabolism2022
2022-09-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-09-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-08-31Kowa Pharmaceuticals America, Inc.$2Food and BeverageCash or cash equivalentSeglentis Drug, Pain Management2022
2022-08-22ABBVIE INC.$14Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-08-17Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-08-17Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-08-17Kowa Pharmaceuticals America, Inc.$2Food and BeverageCash or cash equivalentSeglentis Drug, Pain Management2022
2022-07-13Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-07-13Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-07-13Kowa Pharmaceuticals America, Inc.$6Food and BeverageCash or cash equivalentSeglentis Drug, Pain Management2022
2022-07-12Eli Lilly and Company$419Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2022
2022-07-08ABBVIE INC.$18Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-06-30Kowa Pharmaceuticals America, Inc.$8Food and BeverageCash or cash equivalentSeglentis Drug, Pain Management2022
2022-06-24ABBVIE INC.$12Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-06-06Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-06-06Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-05-16Takeda Pharmaceuticals U.S.A., Inc.$300Consulting FeeCash or cash equivalent2022
2022-05-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-05-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-04-19ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2022
2022-04-19ABBVIE INC.$58Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-04-19ABBVIE INC.$16Travel and LodgingIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-04-19ABBVIE INC.$14Food and BeverageCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2022
2022-04-19ABBVIE INC.$7Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-04-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-04-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-04-08Eli Lilly and Company$4,610Research paymentIn-kind items and servicesA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2022
2022-04-04ABBVIE INC.$10Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-03-28ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2022
2022-03-28ABBVIE INC.$15Travel and LodgingIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-03-28ABBVIE INC.$11Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-03-09ABBVIE INC.$12Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-03-08Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-03-08Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-03-08ABBVIE INC.$11Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-02-15Takeda Pharmaceuticals U.S.A., Inc.$1,303Consulting FeeCash or cash equivalent2022
2022-02-07Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-02-07Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-02-03Janssen Pharmaceuticals, Inc$14Food and BeverageIn-kind items and servicesXARELTO Drug, Cardiovascular & Metabolism2022
2022-01-31ABBVIE INC.$13Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-01-18ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2022
2022-01-18ABBVIE INC.$53Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-01-18ABBVIE INC.$15Travel and LodgingIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2022
2022-01-18ABBVIE INC.$14Food and BeverageCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2022
2022-01-12Eli Lilly and Company$4,561Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2022
2022-01-11Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2022-01-11Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2022
2021-12-14ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2021
2021-12-14ABBVIE INC.$62Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-12-14ABBVIE INC.$9Travel and LodgingIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-12-14ABBVIE INC.$5Food and BeverageCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2021
2021-12-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2021
2021-12-09Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2021
2021-11-23ABBVIE INC.$13Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-11-06Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2021
2021-11-06Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2021
2021-10-28Janssen Pharmaceuticals, Inc$14Food and BeverageIn-kind items and servicesXARELTO Drug, Cardiovascular & Metabolism2021
2021-10-11Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2021
2021-10-11Takeda Pharmaceuticals U.S.A., Inc.$2,607Consulting FeeCash or cash equivalent2021
2021-10-08Eli Lilly and Company$1,684Research paymentIn-kind items and servicesA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2021
2021-09-22ABBVIE INC.$12Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-09-20Takeda Pharmaceuticals U.S.A., Inc.$4,810Consulting FeeCash or cash equivalent2021
2021-09-20Takeda Pharmaceuticals U.S.A., Inc.$385Travel and LodgingIn-kind items and services2021
2021-09-20Takeda Pharmaceuticals U.S.A., Inc.$123Food and BeverageIn-kind items and services2021
2021-09-13Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-09-13Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-09-07ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2021
2021-09-07ABBVIE INC.$57Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-09-07ABBVIE INC.$14Food and BeverageCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVE2021
2021-09-07ABBVIE INC.$8Travel and LodgingIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-08-24ABBVIE INC.$13Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-08-10Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-08-10Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-07-15Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-07-15Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-06-10Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-06-10Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-06-03Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-05-19ABBVIE INC.$10Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-05-11Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-05-11Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-05-07ABBVIE INC.$15Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-04-27Eli Lilly and Company$6,430Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2021
2021-04-12Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-04-12Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-04-09Takeda Pharmaceuticals U.S.A., Inc.$433Consulting FeeCash or cash equivalent2021
2021-03-26ABBVIE INC.$12Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-03-08Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-03-08Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-03-04Janssen Pharmaceuticals, Inc$14Food and BeverageIn-kind items and servicesXARELTO Drug, Cardiovascular & Metabolism2021
2021-02-11ABBVIE INC.$10Food and BeverageIn-kind items and servicesDALVANCE Drug, ANTI-INFECTIVE2021
2021-02-09Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-02-09Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-01-21ABBVIE INC.$10Food and BeverageIn-kind items and servicesTEFLARO Drug, ANTI-INFECTIVE2021
2021-01-12Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2021-01-12Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2021
2020-12-09Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2020
2020-12-09Takeda Pharmaceuticals U.S.A., Inc.$2,507Consulting FeeCash or cash equivalent2020

The latest 200 records of 396.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-31Novartis Pharmaceuticals CorporationCOVENANT MEDICAL CENTER$89Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-08-19Novartis Pharmaceuticals CorporationCOVENANT MEDICAL CENTER$2,744Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-06-30Novartis Pharmaceuticals CorporationCOVENANT MEDICAL CENTER$10,319Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-06-24Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$1,251ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2025
2025-03-04Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$1,345ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2025
2025-02-11Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$55,111ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2025
2025-02-10Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$5,284A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2025
2025-01-30Novartis Pharmaceuticals CorporationMERCYONE WATERLOO MEDICAL CENTER$6,164Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-01-28Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$86,846A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2025
2025-01-21Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$29,686ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2025
2024-07-09CSL BehringMercyone Waterloo Medical Center$3,200A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-06-03CSL BehringMercyone Waterloo Medical Center$8,512A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-04-01Novartis Pharmaceuticals CorporationCOVENANT MEDICAL CENTER$20,381Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2024
2024-03-15CSL BehringMercyone Waterloo Medical Center$3,000A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-15CSL BehringMercyone Waterloo Medical Center$1,500A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-15CSL BehringMercyone Waterloo Medical Center$1,600A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-01Novartis Pharmaceuticals CorporationMercyone Waterloo Medical Center$7,628Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2024
2024-02-06Eli Lilly and CompanyMercyone Waterloo Medical Center$225,154ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2024
2024-01-25Eli Lilly and CompanyMercyone Waterloo Medical Center$4,143ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2024
2024-01-25Eli Lilly and CompanyMercyone Waterloo Medical Center$4,164ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2024
2024-01-09Eli Lilly and CompanyMercyone Waterloo Medical Center$2,737A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2024
2024-01-02Eli Lilly and CompanyMercyone Waterloo Medical Center$146,975A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2024
2024-01-02Eli Lilly and CompanyMercyone Waterloo Medical Center$363,933ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2024
2023-09-19Novartis Pharmaceuticals CorporationCOVENANT MEDICAL CENTER$16,250Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2023
2023-07-11Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$2,244A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3)2023
2023-05-09Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$168ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2023
2023-05-02Esperion Therapeutics, Inc.MERCYONE WATERLOO MEDICAL CENTER$15,026A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2023
2023-03-31Novartis Pharmaceuticals CorporationCOVENANT MEDICAL CENTER$3,989Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2023
2023-03-10Novartis Pharmaceuticals CorporationMERCYONE WATERLOO MEDICAL CENTER$14,375Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2023
2023-01-26Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$8,133ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER2023
2023-01-26Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$6,846A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2)2023
2023-01-18Esperion Therapeutics, Inc.MERCYONE WATERLOO MEDICAL CENTER$2,000A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2023
2023-01-09Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$289,171ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER2023
2023-01-03Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$371,562A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3)2023
2023-01-03Eli Lilly and CompanyMERCYONE WATERLOO MEDICAL CENTER$520,339A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2)2023
2022-08-28Eli Lilly and CompanyMercyone Waterloo Medical Center$1,199ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-11Eli Lilly and CompanyMercyone Waterloo Medical Center$5,628ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$50A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$82A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$82A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$82A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$82A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$105A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$82A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$82A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$82A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$82A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$105A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$105A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$105A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$105A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$50A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$50A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$50A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$338A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$338A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$586A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$586A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$586A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$586A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$586A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,261A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-24Esperion Therapeutics, Inc.NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC$338A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-24Esperion Therapeutics, Inc.NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-24Esperion Therapeutics, Inc.NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC$226A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-24Esperion Therapeutics, Inc.NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC$586A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-03Eli Lilly and CompanyMercyone Waterloo Medical Center$315,458A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2022
2022-04-25Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$105A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-25Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$586A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-25Esperion Therapeutics, Inc.Mercyone Waterloo Medical Center$1,800A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-15Novartis Pharmaceuticals CorporationCOVENANT MEDICAL CENTER$36,907RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CAR2022
2022-03-01Esperion Therapeutics, Inc.NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC$586A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-03-01Esperion Therapeutics, Inc.NORTHEAST IOWA MEDICAL EDUCATION FOUNDATION INC$338A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Black Hawk CountyWaterloo city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Waterloo, IA, county Black Hawk County, IA, state Iowa; placed by its city name.

MeasurePlace (city or town)
Waterloo, IA
County
Black Hawk County, IA
State
Iowa
Population B0100367,008131,0493,210,507
Population, 2020 census P167,314131,1443,190,369
Median age B0100236.735.738.6
Under 18 B0100124.5%21.9%22.9%
65 and over B0100117.0%17.7%18.1%
Households B1100129,28354,5631,315,707
Foreign born B0500210.1%6.5%5.9%
Median household income B19013$57,480$66,417$75,059
Median family income B19113$72,697$86,857$97,491
Per capita income B19301$32,837$37,541$40,877
Poverty rate B1700116.6%14.9%11.1%
Unemployment rate B230255.3%4.6%3.6%
Civilian labor force B2302534,28170,1241,699,994
Mean commute (minutes) B0801315.915.919.8
Bachelor's degree or higher B1500321.8%30.3%31.4%
Housing units B2500132,14358,9911,437,699
Owner-occupied B2500362.1%66.2%71.7%
Renters B2500337.9%33.8%28.3%
Median home value B25077$152,600$188,900$208,000
Median gross rent B25064$923$989$972
White, not Hispanic B0300265.5%78.1%82.3%
Black B0300216.4%9.1%3.8%
Hispanic or Latino B030028.4%5.2%7.3%
Asian B030023.2%2.7%2.5%
American Indian and Alaska Native B030020.1%0.1%0.2%

Economy now FRED unemployment 3.2% in Sep 2026 (3.4% a year earlier); per capita personal income $67,321 in 2025, up 28% in five years (+2.8% after inflation); Unemployment rate: 3.6% in Sep 2016 to 3.2% in Sep 2026; low 2.5%, high 11.0% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Waterloo, IA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.